UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 26

Sortiert nach

Vaccination process of immunocompromised patients in the Netherlands: Current challenges and potential solutions

Vaccine: X, 2023-08, Vol.14, p.100340-100340, Article 100340

2023

Volltextzugriff (PDF)

Meningococcal serogroup A, C, W₁₃₅ and Y conjugated vaccine: a cost-effectiveness analysis in the Netherlands

PloS one, 2013-05, Vol.8 (5), p.e65036-e65036

2013

Volltextzugriff (PDF)

Cost of Illness Analysis of Invasive Meningococcal Disease Caused by Neisseria Meningitidis Serogroup B in the Netherlands—a Holistic Approach

Infectious diseases and therapy, 2024-03, Vol.13 (3), p.481-499

2024

Volltextzugriff (PDF)

Cost-effectiveness of a male catch-up human papillomavirus vaccination program in the Netherlands

Preventive medicine reports, 2022-08, Vol.28, p.101872-101872, Article 101872

2022

Volltextzugriff (PDF)

Cost-effectiveness analysis of various pertussis vaccination strategies primarily aimed at protecting infants in the Netherlands

Clinical therapeutics, 2010-08, Vol.32 (8), p.1479-1495

2010

Volltextzugriff (PDF)

Cost-effectiveness of adolescent pertussis vaccination for the Netherlands: using an individual-based dynamic model

PloS one, 2010-10, Vol.5 (10), p.e13392-e13392

2010

Volltextzugriff (PDF)

Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands

BMC infectious diseases, 2013-02, Vol.13 (1), p.75-75, Article 75

2013

Volltextzugriff (PDF)

On Discounting of Health Gains from Human Papillomavirus Vaccination: Effects of Different Approaches

Value in health, 2012-05, Vol.15 (3), p.562-567

2012

Volltextzugriff (PDF)

Cost-effectiveness analysis of a gender-neutral human papillomavirus vaccination program in the Netherlands

Vaccine, 2020-06, Vol.38 (30), p.4687-4694

2020

Volltextzugriff (PDF)

Practical Implications of Differential Discounting of Costs and Health Effects in Cost-Effectiveness Analysis

Value in health, 2011-12, Vol.14 (8), p.1173-1174

2011

Volltextzugriff (PDF)

Until Which Age Should Women Be Vaccinated Against HPV Infection? Recommendation Based on Cost-effectiveness Analyses

The Journal of infectious diseases, 2011-08, Vol.204 (3), p.377-384

2011

Volltextzugriff (PDF)

Economic evaluation of vaccines: specificities and future challenges illustrated by recent European examples

Expert review of vaccines, 2013-05, Vol.12 (5), p.555-565

2013

Volltextzugriff (PDF)

Equity in human papilloma virus vaccination uptake?: sexual behaviour, knowledge and demographics in a cross-sectional study in (un)vaccinated girls in the Netherlands

BMC public health, 2014-03, Vol.14 (1), p.288-288, Article 288

2014

Volltextzugriff (PDF)

Behavioral pattern analysis and dopamine release in quinpirole-induced repetitive behavior in rats

Journal of psychopharmacology (Oxford), 2011-12, Vol.25 (12), p.1712-1719

2011

Volltextzugriff (PDF)

Accumulating evidence for the case of differential discounting

Expert review of clinical pharmacology, 2013-01, Vol.6 (1), p.1-3

2013

Volltextzugriff (PDF)

Dynamic models for health economic assessments of pertussis vaccines: what goes around comes around

Expert review of vaccines, 2012-12, Vol.11 (12), p.1415-1428

2012

Volltextzugriff (PDF)

Reviewing and piloting methods for decreasing discount rates; someone, somewhere in time

Expert review of pharmacoeconomics & outcomes research, 2013-08, Vol.13 (4), p.523-547

2013

Volltextzugriff (PDF)

Letter to the Editor

Clinical therapeutics, 2013-07, Vol.35 (7), p.1046

2013

Volltextzugriff (PDF)

Letter to the Editor

Clinical therapeutics, 2013-07, Vol.35 (7), p.1046-1047

2013

Volltextzugriff (PDF)

Letter to the Editor

Clinical therapeutics, 2013, Vol.35 (7), p.1046-1047

2013

Volltextzugriff (PDF)

Letter to the editor

Clinical therapeutics, 2013-07, Vol.35 (7), p.1046-1047

2013

Volltextzugriff (PDF)

Meningococcal Serogroup A, C, W135 and Y Conjugated Vaccine: A Cost-Effectiveness Analysis in the Netherlands. e65036

PloS one, 2013-05, Vol.8 (5)

2013

Volltextzugriff (PDF)

Efficiency of human papillomavirus vaccination--estimates based on Dutch cost effectiveness analyses

Nederlands tijdschrift voor geneeskunde, 2009, Vol.153, p.A356

2009

Volltextzugriff (PDF)

An Updated Analysis of the Impact of HPV Vaccination Based on Long-term Effectiveness in the Netherlands

Infectious diseases and therapy, 2023-08, Vol.12 (8), p.2135-2145

2023

Volltextzugriff (PDF)

Cost-Utility Analysis of Human Papillomavirus Vaccination and Cervical Screening on Cervical Cancer Patient in Indonesia

Value in health regional issues, 2016-05, Vol.9, p.84-92

2016

Volltextzugriff (PDF)

1 – 25 von 26

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(25)
Mit Volltextzugriff
(21)

Publikationsform

Artikel
(26)

Sprache

Englisch
(25)
Niederländisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(18)
Life Sciences & Biomedicine
(17)
Humans
(16)
Cost-Benefit Analysis
(11)
Female
(11)
Vaccination
(9)
Infectious Diseases
(8)
Netherlands
(8)
Uterine Cervical Neoplasms - Prevention & Control
(8)
Vaccines
(8)
Cervical Cancer
(7)
Human Papillomavirus
(7)
Immunization
(7)
Adolescent
(6)
Child
(6)
Immunology
(6)
Internal Medicine
(6)
Models, Economic
(6)
Papillomavirus Infections - Prevention & Control
(6)
Papillomavirus Vaccines - Economics
(6)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Vaccination process of immunocompromised patients in the Netherlands: Current challenges and potential solutions

Meningococcal serogroup A, C, W₁₃₅ and Y conjugated vaccine: a cost-effectiveness analysis in the Netherlands

Cost of Illness Analysis of Invasive Meningococcal Disease Caused by Neisseria Meningitidis Serogroup B in the Netherlands—a Holistic Approach

Cost-effectiveness of a male catch-up human papillomavirus vaccination program in the Netherlands

Cost-effectiveness analysis of various pertussis vaccination strategies primarily aimed at protecting infants in the Netherlands

Cost-effectiveness of adolescent pertussis vaccination for the Netherlands: using an individual-based dynamic model

Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands

On Discounting of Health Gains from Human Papillomavirus Vaccination: Effects of Different Approaches

Cost-effectiveness analysis of a gender-neutral human papillomavirus vaccination program in the Netherlands

Practical Implications of Differential Discounting of Costs and Health Effects in Cost-Effectiveness Analysis

Until Which Age Should Women Be Vaccinated Against HPV Infection? Recommendation Based on Cost-effectiveness Analyses

Economic evaluation of vaccines: specificities and future challenges illustrated by recent European examples

Equity in human papilloma virus vaccination uptake?: sexual behaviour, knowledge and demographics in a cross-sectional study in (un)vaccinated girls in the Netherlands

Behavioral pattern analysis and dopamine release in quinpirole-induced repetitive behavior in rats

Accumulating evidence for the case of differential discounting

Dynamic models for health economic assessments of pertussis vaccines: what goes around comes around

Reviewing and piloting methods for decreasing discount rates; someone, somewhere in time

Letter to the Editor

Letter to the Editor

Letter to the Editor

Letter to the editor

Meningococcal Serogroup A, C, W135 and Y Conjugated Vaccine: A Cost-Effectiveness Analysis in the Netherlands. e65036

Efficiency of human papillomavirus vaccination--estimates based on Dutch cost effectiveness analyses

An Updated Analysis of the Impact of HPV Vaccination Based on Long-term Effectiveness in the Netherlands

Cost-Utility Analysis of Human Papillomavirus Vaccination and Cervical Screening on Cervical Cancer Patient in Indonesia

Suchergebnisse filtern